ADHD Symptoms and Cannabis Use: The Role of Cannabinoid Receptor 1 and Neural Response Inhibition
Jacqueline Aloumanis, Shan-Ting Chen, J. H. Allen, Chia-Chuan Yu, Sara Jo Nixon, Amanda Elton
medRxiv July 1, 2026 preprint DOI: 10.64898/2026.06.24.26356461 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational longitudinal study with growth mixture modelling |
|---|---|
| Sample size | 466 |
| Population | College students aged 18-19 with varying ADHD symptom severity and cannabis use; fMRI subset of 144 participants |
| Duration | Baseline plus three yearly follow-up questionnaires |
| Measures | fMRI stop-signal task |
| Topics | Cannabis |
| Key findings | Greater ADHD symptoms predicted reduced activation within CNR1-expressing brain regions, which in turn predicted membership in a higher cannabis-use latent class. The authors argue this supports the self-medication hypothesis, with cannabis use possibly linked mechanistically to CB1R-enriched attention and inhibitory networks. |
Abstract
Background: Individuals with attention-deficit hyperactivity disorder (ADHD) are at increased risk for cannabis misuse, with increasing prevalence among young adults. Existing evidence suggests that cannabis can have therapeutic effects on ADHD symptoms, and continued use may be partly driven by perceived improvements in symptom-related deficits. To investigate the neural evidence for these associations, we integrated functional neuroimaging and Allen Human Brain Atlas transcriptomic data to assess neural correlates of ADHD in regions targeted by cannabinoids as predictors of cannabis use. We hypothesized that greater ADHD symptoms would lead to higher cannabis use frequency through associations of ADHD symptoms with functional deficits in cannabinoid receptor type 1 (CB1R; encoded by the CNR1 gene) expressing brain regions.
Methods: We tested 466 college students (ages 18-19) with varying ADHD symptom severity and cannabis use, self-reported at baseline and three yearly-follow up questionnaires. ADHD-related neural deficits were tested in a subset of 144 participants using an fMRI stop-signal task at baseline. Growth mixture modelling categorized participants with similar cannabis use into three latent classes. The covariance between the CNR1 gene expression map and differences in stop-signal task activation were tested as a mediator linking ADHD symptoms and cannabis use.
Results: Greater ADHD symptoms significantly predicted reduced activation within CNR1-expressing regions, which predicted higher-use cannabis class membership.
Conclusions: Our results add support for the self-medication hypothesis for higher rates of cannabis use among individuals with greater ADHD symptoms, which may be mechanistically linked through CB1R-enriched attention and inhibitory networks, highlighting neural targets for prevention and treatment.
Comparable studies
Other observational and cohort studies on cannabis, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| High-potency cannabis and the risk of psychosis People with first episode of psychosis and healthy controls from the local population | 2009 | Case-control study | n = 454 |
| Ayahuasca-Assisted Therapy for Addiction: Results from a Preliminary Observational Study in Canada Rural aboriginal population | 2013 | Observational study | |
| Impaired cognitive performance in drug free users of recreational ecstasy (MDMA) Otherwise healthy young people | 2000 | Observational | |
| Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study Individuals from the general population in Germany aged 14-24 at baseline | 2011 | Observational cohort | n = 1,923 |
| Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases Patients treated for cannabis-induced psychotic symptoms in Denmark between 1994 and... | 2005 | Observational cohort | n = 535 |
Citations in the library
Cites 5
- Review of the Endocannabinoid System Biological Psychiatry: Cognitive Neuroscience and Neuroimaging August 1, 2020
- Adolescent cannabis use, cognition, brain health and educational outcomes: A review of the evidence. European Neuropsychopharmacology April 5, 2020
- Cannabis effects on brain structure, function, and cognition: considerations for medical uses of cannabis and its derivatives The American Journal of Drug and Alcohol Abuse July 31, 2019
- Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers Molecular Psychiatry July 12, 2011
- Delta9-tetrahydrocannabinol is a full agonist at CB1 receptors on GABA neuron axon terminals in the hippocampus. Neuropharmacology 2010